alcohol brands

335 registered brands containing alcohol in Tanzania.

Alcohol 2D chemical structure

2D structure

Alcohol

PubChem CID 702

Molecular formula: C2H6O

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Source: PubChem (NCBI) · compound 702

Product Manufacturer Status Country
BUTASAL-100
Solution for injection
Interchemie Werken ''de Adelaar'' B.v Registered/Compliant Tanzania
CALCURY
Tablets
Charak Pharma Registered/Compliant Tanzania
CALCURY TABLETS
Tablets
Charak Pharma Pvt. Ltd Registered/Compliant Tanzania
CANDIZOLE CREAM
Cream
Bal Pharma Registered/Compliant Tanzania
Cani-Maks
Cream
S Kant Healthcare Registered/Compliant Tanzania
Cardinol
Tablets
Cosmos Registered/Compliant Tanzania
CARDINOL 50MG FILM COATED TABLETS
Tablets
Cosmos Registered/Compliant Tanzania
CARDIONE 25
Film Coated Tablet
Brawn Laboratories Registered/Compliant Tanzania
Cardivas 12.5
Tablets
Sun Pharmaceuticals Registered/Compliant Tanzania
CEFLIN-200
Oral tablet
Lincoln Pharmaceuticals Limited Registered/Compliant Tanzania
Cinod -10
Film Coated Tablet
Ajanta Pharma Registered/Compliant Tanzania
CINOD 5
Film Coated Tablet
Ajanta Pharma Registered/Compliant Tanzania
Ciprofloxacin
Tablets
Medopharm Registered/Compliant Tanzania
Ciprosol-200 Oral
Oral Solution
Interchemie Registered/Compliant Tanzania
CLONEM-G
Cream
Nem Laboratories Registered/Compliant Tanzania
CLOPA
Film Coated Tablet
Pinnacle Life Science Registered/Compliant Tanzania
Clopact-75
Tablets
Ipca Laboratories Registered/Compliant Tanzania
CLOTRILIN
Cream
Lincoln Pharmaceuticals Registered/Compliant Tanzania
Co-Irda
Film Coated Tablet
Nobel Ilaç Registered/Compliant Tanzania
Co-Irda
Film Coated Tablet
Nobel Ilaç Registered/Compliant Tanzania
COLIMEND 1.2 g
Tablets
Annora Pharma Registered/Compliant Tanzania
COMBIART
Tablets
Universal Corporation Registered/Compliant Tanzania
CONBET
Cream
Kremoint Pharma Private Limited Registered/Compliant Tanzania
Cool Mint Listerine Johnson & Johnson Registered/Compliant Tanzania
COREBACT
Cream
Front Pharmaceutical PLC Registered/Compliant Tanzania
CUPIRIN Tablets
Tablet, Enteric Coated
Cure Afya Registered/Compliant Tanzania
Dalacin Injection
Solution for injection
Pfizer Registered/Compliant Tanzania
DAPZIN 5-M PLUS
Film Coated Tablet
Micro Labs Registered/Compliant Tanzania
Dapzin10-M
Film Coated Tablet
Micro Labs Registered/Compliant Tanzania
DAXIMRA 110
Capsules
Mylan Laboratories Registered/Compliant Tanzania
DAXIMRA 150
Capsules
Mylan Laboratories Registered/Compliant Tanzania
DAXIMRA 75
Capsules
Mylan Laboratories Registered/Compliant Tanzania
Dazolic
Tablets
Sun Pharma Registered/Compliant Tanzania
Defal
Oral Suspension
Faes Farma Registered/Compliant Tanzania
Defal Drops
Oral Suspension
Faes Farma Registered/Compliant Tanzania
Demtris Cream
Cream
Laboratorios Vitoria Registered/Compliant Tanzania
DERMAGUARD FORTE CREAM
Cream
Coral Laboratories Registered/Compliant Tanzania
Dermazole Cream
Cream
Kusum Healthcare Registered/Compliant Tanzania
DERMOLIN
Cream
Lincoln Pharmaceuticals Registered/Compliant Tanzania
Dermovate cream
Cream
Delpharm Registered/Compliant Tanzania
Dexaphan
Solution for injection
Pharma Swede Registered/Compliant Tanzania
Dexona Vet Injection
Solution for injection
Zenex Animal Health Registered/Compliant Tanzania
DIAZAC 10
Tablets
Ajanta Pharma Registered/Compliant Tanzania
DIAZAC 5
Tablets
Ajanta Pharma Registered/Compliant Tanzania
Diazac M 10/1000
Oral tablet
Ajanta Pharma Limited Registered/Compliant Tanzania
DIAZAC M ER 10/500
Oral tablet
Ajanta Pharma Limited Registered/Compliant Tanzania
DICLOKAS
Solution for injection
Ratnatris Pharmaceuticals Pvt. Ltd Registered/Compliant Tanzania
Dicloran MS
Gel
Unique Pharmaceutical Laboratories Registered/Compliant Tanzania
Diclox 2.5% Oral solution
Solution, Oral
Farmers Centre Registered/Compliant Tanzania
Dicorate ER 250
Extended Release Tablet
Sun Pharmaceutical Industries Registered/Compliant Tanzania
1234